ERBB2 and bladder transitional cell carcinoma: Additionally, ongoing clinical trials are investigating vedotin-tislelizumab as neoadjuvant treatment for HER2-positive locally advanced bladder urothelial carcinoma patients (Wen et al., 2024; Wen et al., 2022).